key: cord-0980546-titvzo31 authors: Montopoli, M.; Zumerle, S.; Vettor, R.; Rugge, M.; Zorzi, M.; Catapano, C. V.; Carbone, G. M.; Cavalli, A.; Pagano, F.; Ragazzi, E.; Prayer-Galetti, T.; Alimonti, A. title: Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532) date: 2020-05-06 journal: Ann Oncol DOI: 10.1016/j.annonc.2020.04.479 sha: 984ca7e3c9a03d6dc63933889f407606f265ac2d doc_id: 980546 cord_uid: titvzo31 Background Cell entry of SARS-CoV-2 depends on binding of the viral spike (S) proteins to ACE2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is upregulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene. First- or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections. Materials and methods We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the COVID-19 pandemic. The parameters used for each COVID-19 positive patient were gender, hospitalization, admission to intensive care unit (ICU), death, tumor diagnosis, prostate cancer diagnosis, and androgen-deprivation therapy (ADT). Results There were 9280 SARS-CoV-2 positive patients in the Veneto on April 1, 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 Million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2. Comparing the total number of SARS-CoV-2 positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared to patients who did not receive ADT (OR 4.05; 95% CI 1.55-10.59). A greater difference was found comparing prostate cancer patients receiving ADT to patients with any other type of cancer (OR 5.17; 95% CI 2.02-13.40). Conclusion Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections than non-cancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections. Background: Cell entry of SARS-CoV-2 depends on binding of the viral spike (S) proteins to ACE2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgenregulated gene that is upregulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene. First-or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections. We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the COVID-19 pandemic. The parameters used for each COVID-19 positive patient were gender, hospitalization, admission to intensive care unit (ICU), death, tumor diagnosis, prostate cancer diagnosis, and androgen-deprivation therapy (ADT). Results: There were 9280 SARS-CoV-2 positive patients in the Veneto on April 1, 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population ( TMPRSS2 is a member of the family of Type II Transmembrane Serine Proteases (TTSPs) that are involved in multiple physiological and pathological processes, including cancer and viral infections [6] [7] [8] . In particular, TMPRSS2 has been implicated as a critical host cell factor for the spread of several clinically relevant viruses, including influenza A viruses, SARS-CoV and MERS-CoV coronaviruses [9] [10] [11] [12] [13] [14] . Recent studies report that the new SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) for cell entry, followed by proteolytic cleavage of the S protein by TMPRSS2 allowing the fusion of viral and cellular membranes 15, 16 . Moreover, in vitro evidence indicates that TMPRSS2 inhibition by camostat mesylate may be beneficial to prevent the infection of SARS-CoV-2 15 . TMPRSS2 is highly expressed in both localized and metastatic prostate cancers 17, 18 and its transcription is regulated by the androgen receptor (AR) 17 . Intriguingly, it has been shown that AR regulates TMPRSS2 expression also in non-prostatic tissues, including lung. In vitro and in vivo results show that androgen administration induces TMPRSS2 expression in human lung epithelial cells and that androgen deprivation reduces TMPRSS2 transcription in murine lung 19 . The androgen-dependent regulation of TMPRSS2 expression in the lung may explain the increased susceptibility of men to develop SARS-CoV-2 severe infections when compared to women. Given that TMPRSS2 levels are under the control of androgens not only in the prostate but also in the lung, we put forward the hypothesis that Androgen Deprivation Therapies (ADTs) may protect patients affected by prostate cancer from SARS-CoV-2 infections. with or without cancer, were obtained from the following data sources: 1) the Veneto Archive of COVID-19 positive subjects, updated on April 1, 2020, 2) the Tumor Registry Archive, 3) the Confidence Interval (CI) for OR was obtained using the Miettinen-Nurminen method 20 . Pvalue was calculated according to Sheskin 21 . Comparisons among frequencies were obtained with the chi-square test. Statistical significance was considered for P< 0.05. We extracted data regarding 9280patients with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in the Veneto. The average age of patients was 73 years for hospitalized, 67 years for ICU-hospitalized, and 81 for deceased patients. Although women were infected at a higher prevalence than men (44% men; 56% women), male patients (n=4532, 0.2% of the total Veneto male population of 2,399,783) developed more severe forms of the disease (Figure 1 ). Men were more frequently hospitalized (60% men; 40% women), represented the vast majority of ICU-hospitalized patients (78% men; 22% women), and accounted for more deaths (62% men; 38% women) ( Figure 1 ). These data are in line with recent results from another study, reporting a more severe outcome for men infected by SARS-CoV-2 22 . indicate that androgen deprivation in prostate cancer patients is associated with a reduced probability to develop SARS-CoV-2 infections and with more positive infection outcomes. Among patients with severe atypical pneumonia, the mortality rate is very high 25, 26 . Two and TGFβ by immune cells, and decrease the antibody response to viral infections 37 . In this respect, it is worth noticing that recent evidence demonstrates that neutrophils are responsible for the cytokine storm syndrome, observed in patients with severe COVID-19 37, 38 . Besides androgens, other steroid hormones (e.g., estrogen, glucocorticoids) may enhance TMPRSS2 expression through binding of their respective nuclear receptors to responsive elements (e.g., ERE, GRE) in the gene promoter, thereby explaining the severity of infections in some cases of female patients 39, 40 . Therefore, inhibition of these regulatory pathways through already available therapies, may also decrease the severity of SARS- The authors have declared no conflicts of interest. Percentage of male patients infected with SARS-CoV-2 in Veneto divided by hospitalization, ICU, and death. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China A pneumonia outbreak associated with a new coronavirus of probable bat origin A Novel Coronavirus from Patients with Pneumonia in China Clinical Characteristics of Coronavirus Disease 2019 in China Type II transmembrane serine proteases Type II transmembrane serine proteases in cancer and viral infections Type II transmembrane serine proteases as potential target for anti-influenza drug discovery Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2 TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma Androgen receptor and androgen-dependent gene expression in lung Comparative analysis of two rates Handbook of parametric and nonparametric statistical procedures Sex difference and smoking predisposition in patients with COVID-19 Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China COVID-19 in Italy: momentous decisions and many uncertainties COVID-19 and Italy: what next? Lancet Identification of a novel coronavirus in patients with severe acute respiratory syndrome A novel coronavirus associated with severe acute respiratory syndrome Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075 Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgenregulated gene expression in advanced prostate cancer cells CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer Sex differences in immune responses Targeting potential drivers of COVID-19: Neutrophil extracellular traps Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade Nuclear receptor ERRalpha and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer We thank N. D'Elia for the help to draft and revise the manuscript, Dr Francesca Russo of the Veneto Region for providing data on Sars-CoV-2 infected patients. Where zero frequency occurred, causing problems with computation algorithm for OR, 0.5 was added to the compared terms (Haldane-Anscombe correction).